Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction

NCT00732745 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Lost funding for Phase II portion of study

Conditions

Adenocarcinoma of the Gastroesophageal Junction
Esophageal Cancer

Interventions

DRUG: docetaxel
DRUG: oxaliplatin
DRUG: vandetanib
OTHER: placebo

Sponsor

Case Comprehensive Cancer Center

Collaborators

[object Object]